RA
Human recombinant interleukin-1 receptor antagonist (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of rheumatoid arthritis (RA).
Human recombinant <span class="gene" id="7706905-1-18-51">interleukin-1 receptor antagonist</span> (rhIL-1ra), a 17.2 kd protein is currently in clinical trials for the treatment of <span class="disease" id="7706905-1-135-155">rheumatoid arthritis</span> (<span class="disease" id="7706905-1-157-159">RA</span>).